سقوط حتمي: الوظائف الإدارية، إدخال البيانات، ومعالجة التأمين الروتيني (الأتمتة تفوقت تماماً).
نجاة بأعجوبة: أطباء الأشعة والصيادلة (دورهم سيتحول من التنفيذ إلى الإشراف والمراجعة على الأنظمة الذكية).
الفوز الحقيقي: الجراحون، الأطباء النفسيون، والممرضون (حيث لا غنى عن اليد الخبيرة والتعاطف الإنساني واللمسة الحية).
الذكاء الاصطناعي لا يلغي الطب، بل يحذف "الروتين" ويبقي على "الإنسان".
denis Moro-Sibilot retweeted
Could an overlooked immune cell help treat small cell #LungCancer?
Researchers at WEHI in Melbourne, working with teams in Cologne and London, found that immune cells called gamma delta T cells can recognise and kill small cell lung cancer cells, even when the tumour is hiding from the rest of the immune system.
People whose tumours had more of these cells tended to live longer on immunotherapy. In the lab, two existing drugs made the cells better at killing the cancer.
It's early research, but small cell lung cancer urgently needs new options.
doi.org/10.1016/j.ccell.2026…

ALT News collage of a Cancer Cell article published 12 October 2026, titled 'γδ T cells modulate anti-tumor immunity in small cell lung cancer' by Jin Ng, Kate D. Sutherland and colleagues. A news clipping reads: The discovery, reported in the journal Cancer Cell by researchers at WEHI, revealed that patients with greater numbers of these specialized immune cells tended to survive longer. Bold text asks: Could an overlooked immune cell help treat small cell lung cancer? Below, part of the paper's graphical abstract shows lungs with immune cells entering a tumour, and gamma delta T cells killing a small cell lung cancer cell, with the drugs tarlatamab and zoledronate labelled.
denis Moro-Sibilot retweeted
🔥HARMONi: The FDA has issued a complete response letter to Summit Therapeutics, declining to approve the PD-1xVEGF bispecific ivonescimab
🆙 @SMMT_TX
👥Patients: EGFR-mutated, locally advanced or metastatic non-squamous NSCLC, previously treated with a third-generation EGFR TKI
3⃣Phase III
⚖️Ivonescimab + platinum-containing chemotherapy
⚖️Placebo + platinum-containing chemotherapy
🔢NCT06396065
#LCSM @OncoAlert @Larvol @EGFRResisters
🔗 smmttx.com/news/press-releas…
🆙#WCLC26 #LCSM Oral Session
🔥HARMONi: Ivonescimab-Chemo vs Placebo-Chemo in EGFR-TKI-Resistant, EGFR-Mutated NSCLC: Updated Overall Survival Analysis
🎙️ @APassaroMD
🔢OA14.04
🎯mOS 17.5 vs 14.0m in Western Cohort (HR 0.76)
🎯ITT mOS 16.8 vs 14.0mo (HR 0.76)
🎯No New Safety Signals
☑️NCT06396065
🔗 cattendee.abstractsonline.co…
@OncoAlert @Larvol @IASLC @EGFRResisters
denis Moro-Sibilot retweeted
A new single-cell atlas of non-small-cell #LungCancer found that standard staging alone can get a patient's risk wrong, in both directions.
A quarter of people staged as stage I were actually high risk. A small group of stage IV patients had survival as good as early stage disease.
This is exactly the point Lung Cancer Europe has long made through its Get Checked! campaign: a stage label is not the whole picture.
Full story: lungcancereurope.eu/news/why…
denis Moro-Sibilot retweeted
1/2
🫁🫁 EGFRm+ LUADs to SCLC transformation 🫁🫁
💥💥Osimertinib + Platinum + Etoposide
💥💥EGFR / TP53 / RB-1 mutant lung cancer
💥💥Translational research
#Lungcancer
#egfr
#SCLC
@ScienceMagazine
@ScienceTM
denis Moro-Sibilot retweeted
Can you prevent small cell transformation in high risk EGFR mutant NSCLC with osimertinib + platinum/etoposide? No. Prospective trial with high response rate, but also high rate of transformation.
By Helena Yu and MSK colleagues
published in @ScienceTM science.org/doi/10.1126/scit…
denis Moro-Sibilot retweeted
🚨 Another HER3 ADC delivers in EGFR-mutant lung cancer!
Published in @TheLancet, the phase III HERON-Lung01 trial evaluated ruzaltatug rezetecan vs platinum-pemetrexed after EGFR-TKI progression.
🔬 498 patients | Key results:
📊 Median PFS: 8.3 vs 5.4 months
🔥 HR 0.47, a 53% reduction in progression/death hazard
⚠️ Grade ≥3 TRAEs: 41% vs 39%
My take: Another positive phase III ADC trial in EGFR-mutant NSCLC. Promising efficacy, but immature follow-up, pending OS data and an all-China population warrant caution.
The post-TKI treatment landscape is getting crowded!
@oncoalert #LungCancer #NSCLC #ADC
Full paper link in comment below ⬇️
denis Moro-Sibilot retweeted
Dalmelitinib Plus Aumolertinib in Advanced #NSCLC Patients With EGFR-TKI Resistance and MET Amplification: A Randomized Phase 3 Trial.
Read the full article. bit.ly/3UqqJLh
#LungCancer
denis Moro-Sibilot retweeted
Always enjoy discussing the latest data with @high5md - this session on the biggest impact data from #ESMO26, gaining perspectives from Drs. @Griesinger35711 @Alfdoc2 @HendriksLizza @nicogirardcurie @DMSLung @DrRiyazShah @MartinReck2
high5oncology.tv/meeting-cov…
denis Moro-Sibilot retweeted
IFCT ONCOBRAF study 🇫🇷 #ESMO26, Encorafenib + Binimetinib shows comparable performance 1L & 2L (mPFS: 11.1 & 9.2 mo) in #BRAF V600mut NSCLC pts, with prolonged survival of 41.1 (1L) and 37.5 mo (2L) confirming this combo as a standard. Come by to learn more and chat @C_Ricordel
denis Moro-Sibilot retweeted
🆙#ESMO26 Rapid Oral II: #LCSM Mets
🔥IFCT-2103 DIAL: Analysis of the Phase 2 Part of a Phase 2-3 Randomized Trial, Comparing Continuation Pembrolizumab (± Pemetrexed) up to 2 Years Versus Observation (± Pemetrexed), in Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Disease Control (DC) at 6 Months
🎙️Dr. Anne-Claire Toffart
🔢2618RO
🎯Similar 18-Mo OS With De-escalation (Observation) vs Continuation: 88.1% vs 83.3% (n=84)
🎯Lower irAEs With De-escalation (47.8% vs 85.1%)
🎯Phase 3 Accrual Ongoing
☑️NCT05255302
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
🆙#ESMO26 Rapid Oral II: #LCSM Mets
🔥IFCT-2103 DIAL: Analysis of the Phase 2 Part of a Phase 2-3 Randomized Trial, Comparing Continuation Pembrolizumab (± Pemetrexed) up to 2 Years Versus Observation (± Pemetrexed), in Patients With Metastatic Non-Small Cell Lung Cancer (mNSCLC) With Disease Control (DC) at 6 Months
🎙️Dr. Anne-Claire Toffart
🔢2618RO
🎯Similar 18-Mo OS With De-escalation (Observation) vs Continuation: 88.1% vs 83.3% (n=84)
🎯Lower irAEs With De-escalation (47.8% vs 85.1%)
🎯Phase 3 Accrual Ongoing
☑️NCT05255302
🔗 cslide.ctimeetingtech.com/es…
@OncoAlert @Larvol @myESMO @IASLC
denis Moro-Sibilot retweeted
A great presentation by Prof. Anne-Claire Toffart (Grenoble University Hospital), on behalf of the French Intergroup IFCT.
A very encouraging message, since longer is not systematically better! Accrual is continuing : Join the French investigator centers already engaged 🫁
denis Moro-Sibilot retweeted
PARSEE trial- while we might be parseeing the data for a while, on surface they seem per se immediately practice-changing!
Chemo/IO led to impressive benefits for tps score>50 pts over pembro alone when it comes to primary endpoint of PFS, trends for OS, dramatic reduction in early progression (25 to 5% or so) - at cost of anticipated toxicities
Benefit surprisingly just as much in tps >90! Only subset of note w limited benefits - pts>70 yrs
So it seems chemo/IO is now the best SOC for pts w non-AGA tps>50 advanced NSCLC w IO likely most appropriate for frail elderly
Special kudos to Dr. Decroisette and the French GFPC study team for completing such an important trial! Merci!
#lcsm
#ESMO26
denis Moro-Sibilot retweeted
#ESMO26 Presidential 1 :
#SCLC DeLLphi-305:
Who would have imagined some years ago that median OS of SCLC would equal that of non-AGA NSCLC!
#Tarlatamab as 1L maintenance with Durvalumab after induction chemoIO in ES-SCLC improved OS from 12.7 to an impressive 21.1m, corresponding to a HR of 0.42.
80% of patients alive and 38% progression-free at 12 months
The dawn of a new era for thoracic oncology and for the lives of our patients 💫✨
@myESMO @SclcSMASHERS
#ESMOAmbassadors
denis Moro-Sibilot retweeted
Off the rousing #ESMO26 oral presentation from Dr. @decroisette, the phase III PERSEE trial with simultaneous publication @Annals_Oncology. Combination of chemotherapy + pembrolizumab superior to pembro in PDL1 high NSCLC: PFS 16.1 vs 6.9m, HR 0.56!
annalsofoncology.org/article…
denis Moro-Sibilot retweeted
⏰ Less is better: 6 months chemo-immunotherapy compare to 2 years lead to similar survival and fewer side effects in patients with 1L stage IV, NSCLC, ICFT-2103 DIAL trial suggests. 🇫🇷 Congratulations for this academic effort !!
However, just informative or definitive evidence? What do you think! #ESMO26 #LCSM
🚨 医学界刚刚扔下一枚核弹:科学家找到了“一键清洗”大脑毒素的物理开关!
只需 10 分钟。不吃药,不动刀。阿尔茨海默病的毒性斑块直接被“冲刷”干净。
你的大脑里有一个专属的废物清理网络(类淋巴系统),负责清扫有毒蛋白和死细胞。
但它极其苛刻:只有在深度睡眠(慢波睡眠)时才会启动。
如果你长期熬夜、睡眠不足,垃圾就会在脑子里发臭、堆积,最终演变成不可逆的认知衰退和阿尔茨海默病。
直到今天,这个死局被打破了。
《Science Advances》最新发表的研究证实:科学家现在可以手动触发这个“深度清洁”程序,完全不需要你睡着。
他们使用 40.68 MHz 的超短波(USW),以非侵入式的方法照射大脑。
短短 10 分钟内,大脑的液体流动开始狂飙。
这些超短波强行将神经元同步到 Delta 状态——这正是深度睡眠时的脑波频率。大脑被瞬间“欺骗”,水通道全开,如同开启了高压水枪,疯狂清洗毒素。
在患有创伤性脑损伤和阿尔茨海默病的小鼠身上,测试结果极其震撼:
🧠 脑水肿迅速消退
🧹 有毒蛋白质被大量清除
📈 认知缺陷实质性逆转
没有开颅手术。没有昂贵的化学药物干预。
仅仅依靠一个特定的物理频率。
人类对抗脑部绝症和衰老的武器库里,多了一把降维打击的重狙。
Readers added context they thought people might want to know
该帖子对Science Advances研究存在夸大渲染。该研究仅在小鼠TBI和阿尔茨海默病模型中显示40.68 MHz超短波可增强类淋巴清除并改善部分症状,尚无人类临床试验数据支持其疗效或“一键清洗”作用。
science.org/doi/10.1126/sc…
denis Moro-Sibilot retweeted
In Beamion LUNG-1 with zongertinib, 8 paired tissue results from pts with PD showed two acquired HER2 mutations: T862A and S783C. Notably absent were T798I (gatekeeper) and C805S (binding site). The acquired mutations not detected in plasma. #WCLC26 @dplanchard
denis Moro-Sibilot retweeted
Early insights into resistance to HER2 TKIs in NSCLC emerged at #WCLC26. Zongertinib & sevabertinib now both approved as 1L+ treatment for advanced NSCLC with a HER2 TKD mt. While efficacy similar, these are distinct agents and we need to learn how to leverage those differences.


















































